- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00532844
A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction
A Phase 2 Randomized Open-label 2-Treatment 2-Sequence 2-Period Crossover PK Study to Compare Plasma Concentrations of BH4 in Subjects With Endothelial Dysfunction Following 14 Days of Treatment by 2 Regimens: 6R-BH4 With Vitamin C and 6R-BH4 Alone
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Jersey
-
Hackensack, New Jersey, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
- Age is ≥ 18 years and ≤ 75 years.
- Willing and able to comply with all study procedures.
If currently receiving treatment with or taking any of the following supplements, be willing and able to discontinue taking them throughout the treatment period:
- Vit C supplements
- Multivitamins containing vit C
- Any other dietary supplements, nutraceuticals, or other over- the-counter products containing vit C
- Vitamin E-containing supplements
- History of cardiovascular disease or cardiovascular risk factors, eg, stable and well-controlled Type 2 diabetes, peripheral arterial disease, obesity, smoking, hypercholesterolemia
- Endothelial dysfunction, documented at screening by an abnormal peripheral arterial tonometry (PAT) of ≤ 1.70.
- Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
- Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomy.
Exclusion Criteria:
- Hypertension secondary to other medical conditions (e.g., renal failure or steroid usage).
- Concurrent disease or condition that would interfere with study participation or safety, such as bleeding disorders; history of syncope or vertigo; severe gastroesophageal reflux disease (GERD); heart failure; symptomatic coronary disease; arrhythmia; serious neurologic disorders, including seizures; organ transplant; or organ failure.
- Type 2 diabetics that are uncontrolled, unstable, newly diagnosed, or have changed therapy in the last three months and all Type 1 diabetics.
- Any severe comorbid condition that would limit life expectancy to < 6 months.
- Serum creatinine > 2.0 mg/dL, or hepatic enzyme concentrations > 2 times the upper limit of normal
- HIV infection, hepatic cirrhosis, other preexisting liver disease, or positive HIV, Hepatitis B or C test at screening.
Concomitant treatment with:
- Drugs known to inhibit folate metabolism (e.g., methotrexate)
- Levodopa
- A phosphodiesterase (PDE) 5 inhibitor (e.g., Viagra®, Cialis®, Levitra®, or Revatio®)
- A PDE 3 inhibitor (e.g., cilostazol, milrinone, or vesnarinone)
- Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
- Myocardial infarction, stroke, or surgery within the last 60 days prior to screening.
- History of alcohol and/or drug abuse or a positive alcohol or drug test at screening.
- Previous treatment with any formulation of BH4.
- Has known hypersensitivity to 6R-BH4 or its excipients.
- Pregnant or breastfeeding at screening, or planning to become pregnant (self or partner) at any time during the study.
- Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sapropterin dihydrochloride
Sapropterin dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
|
Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
Other Names:
|
Experimental: Sapropterin dihydrochloride+Vitamin C
Sapropterin dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
|
Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve (AUC0-12hrs) of Plasma BH4 Concentration
Time Frame: At 30 minutes prior to dosing, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hours after dosing.
|
Plasma BH4 concentration area under the curve (AUC0-12 hrs) at the end of each regimen in subjects with endothelial dysfunction.
|
At 30 minutes prior to dosing, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hours after dosing.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve (AUC0-12hrs) of Plasma BH2 and B Concentration
Time Frame: At 30 minutes prior to dosing, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hours after dosing.
|
Plasma BH2 and B concentration area under the curve (AUC0-12hrs) at the end of each regimen in subjects with endothelial dysfunction.
|
At 30 minutes prior to dosing, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hours after dosing.
|
Area Under the Curve (AUC0-12hours) for Calculated BH4 (From Total Biopterin)
Time Frame: At 30 minutes prior to dosing, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hours after dosing.
|
Total biopterin concentration area under the curve (AUC0-12hours) at the end of each regimen in subjects with endothelial dysfunction is theoretically the sum of BH4, BH2 and B. Biopterin is the metabolite of BH4 after oxidative conversion of BH4 and BH2 to biopterin.
Total biopterin concentrations represent the summation of drug and metabolites: BH4, BH2 and B. The total biopterin concentrations can be converted to BH4 concentration using the conversion factor 2.150.
|
At 30 minutes prior to dosing, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hours after dosing.
|
Ratio of BH2, B and BH4 Calculated From Total Biopterin Area Under the Curve (0-12hours) for Subjects Administered Sapropterin Dihydrochloride With Vitamin C to Subjects Administered Sapropterin Alone.
Time Frame: At 30 minutes prior to dosing, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hours after dosing.
|
Ratio of Mean AUC (0-12 hours) for subjects receiving (Sapropterin dihydrochloride + Vitamin C)/ Mean AUC (0-12 hours) for subjects receiving Sapropterin dihydrochloride alone) for BH4, BH2, B, BH4/BH2 Ratio, and BH4 Calculated from Total Biopterin.
|
At 30 minutes prior to dosing, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hours after dosing.
|
Change From Baseline in Peripheral Arterial Tonometry (PAT)
Time Frame: At Baseline, Day 13 and Day 27
|
PAT measures pulse wave amplitude of the small arteries of the finger as a surrogate to assess endothelial function and arterial stiffness using a finger plethysmographic probe and 5-minute occlusion of the brachial artery.
Endothelial dysfunction, a protocol inclusion criteria, is defined by an abnormal PAT of < or = 1.70.
Change is calculated as follows: end time measurement - starting time measurement.
|
At Baseline, Day 13 and Day 27
|
Change From Baseline in Systolic Blood Pressure (SBP)
Time Frame: At Baseline, Day 13 and Day 27
|
Change is calculated as follows: end time measurement - starting time measurement. Mean daytime systolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) |
At Baseline, Day 13 and Day 27
|
Change From Baseline in Diastolic Blood Pressure (DBP)
Time Frame: At Baseline, Day 13 and Day 27
|
Change is calculated as follows: end time measurement - starting time measurement. Mean daytime diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) |
At Baseline, Day 13 and Day 27
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to 56 ± 3 Days.
|
A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration.
|
Up to 56 ± 3 Days.
|
Change From Baseline in Urinary 8-isoprostane/Creatinine
Time Frame: At Baseline, Day 14 and Day 28
|
Biomarkers of endothelial function, oxidative stress, and inflammation as measured by 8-isoprostane.
|
At Baseline, Day 14 and Day 28
|
Change From Baseline in Cyclic Guanosine Monophosphate (cGMP)
Time Frame: At Baseline, Day 14 and Day 28.
|
Biomarkers of endothelial function, oxidative stress, and inflammation as measured by cyclic guanosine monophosphate (cGMP).
|
At Baseline, Day 14 and Day 28.
|
Change in Urinary Albumin to Creatinine Ratio (mg/g)
Time Frame: Baseline, Day 14 and Day 28
|
Change in Urinary Albumin to Creatinine Ratio (mg/g) from Baseline to Day 14, Baseline to Day 28, and from Day 14 to Day 28
|
Baseline, Day 14 and Day 28
|
Number of Participants With Urinary Albumin to Creatinine Ratio <30 mg/g
Time Frame: Baseline, Day 14 and Day 28
|
Summary of Urinary Albumin to Creatinine Ratio (mg/g) by subjects with ratio <30 mg/g and subjects with ratios >=30 mg/g at Baseline, Day 14 and Day 28
|
Baseline, Day 14 and Day 28
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HTN-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endothelial Dysfunction
-
M.D. Anderson Cancer CenterRecruitingEndothelial Dysfunction | Vascular | Endothelial | EndothelixUnited States
-
Clinica ARS MedicaUnknown
-
University of California, San DiegoCompletedEndothelial Dysfunction
-
M.D. Anderson Cancer CenterCompletedEndothelial DysfunctionUnited States
-
NestléCompleted
-
Société des Produits Nestlé (SPN)Completed
-
General Hospital of Chinese Armed Police ForcesChinese PLA General HospitalUnknown
-
University of ConnecticutCompletedEndothelial DysfunctionUnited States
-
Florida State UniversityRecruitingEndothelial DysfunctionUnited States
-
Kocaeli Derince Education and Research HospitalCompletedEndothelial DysfunctionTurkey
Clinical Trials on Sapropterin Dihydrochloride
-
Providence VA Medical CenterBioMarin Pharmaceutical; LifespanCompletedHeart Failure | Cardiovascular DiseaseUnited States
-
Emory UniversityTerminated
-
BioMarin PharmaceuticalCompletedPhenylketonuria | HyperphenylalaninaemiaUnited States
-
New York State Psychiatric InstituteStanley Medical Research InstituteCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Merck KGaA, Darmstadt, GermanySmerud Medical Research International AS; Merck Serono NorwayCompleted
-
BioMarin PharmaceuticalCompletedPhenylketonuriaItaly, Spain, United Kingdom, Germany
-
University of MiamiCompletedPhenylketonuriaUnited States
-
University of Massachusetts, WorcesterWithdrawnSchizophrenia | Schizo Affective DisorderUnited States
-
Merck KGaA, Darmstadt, GermanyCompleted
-
University of OxfordBioMarin PharmaceuticalUnknownCoronary Artery DiseaseUnited Kingdom